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Correspondence Dominance of Furosemide for
Loop Diuretic Therapy in Heart Failure
Time to Revisit the Alternatives?To the Editor: Diuretics are a mainstay of treatment in both chronic
and acute decompensated heart failure (HF). Studies during the
1990s and early 2000s show that roughly 90% of HF patients
receive at least 1 class of diuretics, particularly a loop diuretic, for
management of chronic (1,2) or acute (3) HF. There are at least 3
widely known loop diuretics—furosemide, bumetanide, and
torsemide—all of which are available as generic formulations.
The available evidence suggests that newer loop diuretics and
furosemide may not be identical. Although markedly limited by
methodological problems and inadequate power, the few existing
pharmacological and clinical studies propose that there might be
superior and more consistent oral bioavailability, longer duration of
action, improved tolerability, and better outcomes with newer loop
diuretics, particularly torsemide, as compared with furosemide
(4–7). Unlike bumetanide for which there is a dearth of clinical
studies, only a few small studies have compared the effects of
torsemide versus furosemide. The TORIC (Torasemide In Con-
gestive Heart Failure) study, an open-label study of 1,337 patients
with New York Heart Association class II to III HF, was the
largest study comparing furosemide with newer loop diuretics.
Although the study had several methodological limitations,
Figure 1 Functional Status and Mortality With Torsemide Comp
No improvement in New York Heart Association functional classification (A) and a
M-H  Mantel-Haenszel.TORIC showed that a greater proportion of patients receiving
torsemide improved their functional class (45.8% vs. 37.2%,
p  0.00017) and that fewer patients receiving torsemide died
(2.2% vs. 4.5%, p  0.05) (5). Additionally, a meta-analysis of the
existing studies (4–6,8–10) (Fig. 1), although demonstrating
remarkable heterogeneity, suggests trends toward improved func-
tional status and mortality with torsemide compared with furo-
semide. Previous research also suggested that torsemide could be
cost-saving compared with furosemide (11). Although there are no
existing clinical studies that have compared the efficacy of newer
loop diuretics versus furosemide for episodes of acute HF, it might
be possible that the newer agents are also beneficial in various
stages of care of acutely decompensated HF. In light of the
potential advantages of newer loop diuretics, we sought to char-
acterize current patterns of use of these agents in U.S. hospitals.
Using the data from the Perspective database, a voluntary,
fee-supported database of more than 500 U.S. hospitals developed
by Premier, Inc., we studied HF hospitalizations during 2009 and
2010 to determine the proportion of adult (age18 years) patients
treated with major loop diuretic formulations. We identified HF
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April 9, 2013:1549–54hospitalizations by the International Classification of Diseases-
Ninth Revision-Clinical Modification principal discharge codes:
402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91,
404.93, or 428.xx.
Among the 274,515 patients with a principal discharge diag-
nosis of HF in the Perspective database, 251,472 (92%) patients
received loop diuretic therapy during their hospital stay. Of those,
218,787 (87%) received furosemide as their only loop diuretic,
6,776 (3%) only received bumetanide, 972 (0.4%) only received
torsemide, whereas 24,937 (10%) were treated with a combination
of these agents.
Most patients with HF received a loop diuretic. However,
torsemide, a new agent with potentially superior clinical effective-
ness, was rarely used. Given the common usage of loop diuretics in
HF and their potential nonequivalence in HF outcomes and
safety endpoints, perhaps it is time for well-designed random-
ized controlled trials, powered for clinical endpoints such as
mortality, readmission, and quality of life, to determine whether
there are differences in the safety and effectiveness of these
agents both for management of chronic HF and for episodes of
acute decompensation.
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Letters to the Editor
The Fontan Operation Starts
With the Cavopulmonary Shunt
We read with great interest the study by Rogers et al. (1) in which
they report their impressive number of 771 patients who under-
went Fontan palliation at their institution. We compliment the
authors on excellent results. Systematic issues in the study design,
however, compel us to comment on their paper.
The Fontan circulation aims at unloading a functionally single
ventricle from its previously volume-overloaded state, while treat-
